Literature DB >> 1676364

Clinical programs for clinical research on AIDS: description of a randomized prospective study of clindamycin versus pyrimethamine for prevention of Toxoplasma gondii infection.

M A Jacobson1, C L Besch, C Child, R Hafner, K Muth, L Deyton.   

Abstract

The risk of toxoplasmic encephalitis complicating AIDS appears largely limited to those HIV-infected patients with serologic evidence of past Toxoplasma gondii infection and low CD4 lymphocyte counts. The Community Programs for Clinical Research on AIDS has initiated a randomized, placebo-controlled trial to determine if clindamycin or pyrimethamine prophylactic regimens are effective and safe in preventing toxoplasmic encephalitis.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1676364     DOI： 10.1007/bf01964462

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  10 in total

1.  Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases.

Authors: 
Journal:  MMWR Suppl       Date:  1987-08-14

2.  Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy.

Authors:  C Leport; F Raffi; S Matheron; C Katlama; B Regnier; A G Saimot; C Marche; C Vedrenne; J L Vilde
Journal:  Am J Med       Date:  1988-01       Impact factor: 4.965

3.  Evaluation of the policy of empiric treatment of suspected Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome.

Authors:  J A Cohn; A McMeeking; W Cohen; J Jacobs; R S Holzman
Journal:  Am J Med       Date:  1989-05       Impact factor: 4.965

4.  Toxoplasma encephalitis in patients with acquired immune deficiency syndrome: diagnosis and response to therapy.

Authors:  C Wanke; C U Tuazon; A Kovacs; T Dina; D O Davis; N Barton; D Katz; M Lunde; C Levy; F K Conley
Journal:  Am J Trop Med Hyg       Date:  1987-05       Impact factor: 2.345

5.  Treatment of toxoplasmic encephalitis with intravenous clindamycin.

Authors:  B R Dannemann; D M Israelski; J S Remington
Journal:  Arch Intern Med       Date:  1988-11

Review 6.  AIDS commentary. Toxoplasmic encephalitis.

Authors:  B J Luft; J S Remington
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

7.  Effect of clindamycin on acute and chronic toxoplasmosis in mice.

Authors:  F G Araujo; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1974-06       Impact factor: 5.191

8.  Neurologic disease as the presenting manifestation of acquired immunodeficiency syndrome.

Authors:  J R Berger; L Moskowitz; M Fischl; R E Kelley
Journal:  South Med J       Date:  1987-06       Impact factor: 0.954

9.  Assessment of therapy for toxoplasma encephalitis. The TE Study Group.

Authors:  H W Haverkos
Journal:  Am J Med       Date:  1987-05       Impact factor: 4.965

10.  Cerebral toxoplasmosis complicating the acquired immune deficiency syndrome: clinical and neuropathological findings in 27 patients.

Authors:  B A Navia; C K Petito; J W Gold; E S Cho; B D Jordan; R W Price
Journal:  Ann Neurol       Date:  1986-03       Impact factor: 10.422
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.